Enlivex Therapeutics Stock Set to Reverse Split on Tuesday, October 27th (NASDAQ:ENLV)

Shares of Enlivex Therapeutics Ltd. (NASDAQ:ENLV) are scheduled to reverse split on Tuesday, October 27th. The 1-16 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, October 26th.

Enlivex Therapeutics Stock Down 13.0%

Shares of ENLV traded down $0.03 during midday trading on Friday, reaching $0.17. The company had a trading volume of 655,132 shares, compared to its average volume of 2,489,173. Enlivex Therapeutics has a 1-year low of $0.17 and a 1-year high of $27.15. The firm has a 50 day simple moving average of $0.79 and a 200-day simple moving average of $6.06.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on ENLV shares. Zacks Research lowered shares of Enlivex Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, October 2nd. Wall Street Zen raised shares of Enlivex Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 29th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Enlivex Therapeutics in a report on Tuesday, September 22nd. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $247.50.

Hedge Funds Weigh In On Enlivex Therapeutics

A number of hedge funds have recently modified their holdings of the business. WINTON GROUP Ltd purchased a new stake in Enlivex Therapeutics in the 2nd quarter valued at about $55,000. Susquehanna International Group LLP lifted its position in Enlivex Therapeutics by 1,428.5% in the second quarter. Susquehanna International Group LLP now owns 157,648 shares of the company’s stock valued at $87,000 after buying an additional 147,334 shares during the last quarter. Finally, Bank of America Corp DE lifted its position in Enlivex Therapeutics by 53.2% in the first quarter. Bank of America Corp DE now owns 130,401 shares of the company’s stock valued at $121,000 after buying an additional 45,303 shares during the last quarter. 1.02% of the stock is currently owned by hedge funds and other institutional investors.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd. is a clinical-stage biotechnology company developing immunotherapies designed to restore immune-system balance in conditions associated with excessive or dysregulated inflammation. The company is based in Israel and trades on the Nasdaq under the symbol ENLV.

Enlivex’s lead product candidate is Allocetra, an investigational, off-the-shelf cell therapy intended to reprogram immune cells known as macrophages and promote immune homeostasis. The therapy is being studied as a potential treatment for severe inflammatory conditions, including sepsis and osteoarthritis of the knee.

The company’s clinical development activities have included studies in Israel and other locations, with programs focused on evaluating Allocetra’s safety and potential efficacy.